南方医科大学学报

南方医科大学学报 ›› 2026, Vol. 46 ›› Issue (1): 83-93.doi: 10.12122/j.issn.1673-4254.2026.01.09

• • 上一篇    下一篇

降脂祛斑方多成分协同调控炎症-代谢网络改善2型糖尿病合并高脂血症：网络药理学与临床验证

李钊泳1(), 周凤华1, 孙晓敏1,2, 赵华杉1, 金瑶1, 何培坤1, 贾钰华1,2()   

  1. 1.南方医科大学，中医药学院，广东 广州 510515
    2.南方医科大学，南方医院，广东 广州 510515
  • 收稿日期:2025-07-24 出版日期:2026-01-20 发布日期:2026-01-16
  • 通讯作者: 贾钰华 E-mail:1425519001@qq.com;jyh@smu.edu.cn
  • 作者简介:李钊泳，在读博士研究生，E-mail: 1425519001@qq.com
  • 基金资助:
    国家自然科学基金(82174299);国家自然科学基金(82574757);贾钰华省名中医传承工作室建设项目

Jiangzhi Quban Recipe improves type 2 diabetes mellitus complicated with hyperlipidemia by multi-target regulation of the inflammation-metabolism network: network pharmacology analysis and clinical validation

Zhaoyong LI1(), Fenghua ZHOU1, Xiaomin SUN1,2, Huashan ZHAO1, Yao JIN1, Peikun HE1, Yuhua JIA1,2()   

  1. 1.School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China
    2.Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
  • Received:2025-07-24 Online:2026-01-20 Published:2026-01-16
  • Contact: Yuhua JIA E-mail:1425519001@qq.com;jyh@smu.edu.cn
  • Supported by:
    National Natural Science Foundation of China(82174299)

RichHTML

2

PDF

26

摘要：

目的 基于网络药理学探讨降脂祛斑方治疗2型糖尿病合并高脂血症的分子机制，并通过动物实验和临床对照试验验证其疗效与安全性。 方法 基于TCMSP和GeneCards数据库筛选降脂祛斑方活性成分和疾病靶点，构建网络图并进行PPI分析、GO功能和KEGG通路富集分析。动物实验用ApoE-/-小鼠高脂饲料造模24周，设空白组、模型组、中药低/高剂量组和辛伐他汀组（n=6），第9~24周给药，检测体质量、血糖、血脂、肝脏病理及炎症因子表达。临床研究纳入72例2型糖尿病合并高脂血症患者，随机分为观察组和对照组，36例/组，均给予二甲双胍联合恩格列净基础治疗，观察组加用降脂祛斑方，对照组加用辛伐他汀，治疗12周后观察相关指标变化。 结果 网络药理学筛得65个潜在靶点，核心成分包括槲皮素、山奈酚、木犀草素等，关键靶点为IL-6、IL-1β、TNF-α等。富集分析显示主要涉及炎症反应、糖尿病并发症等通路。动物实验显示，降脂祛斑方呈剂量依赖性改善体质量、血糖及血脂（P<0.05），高剂量组肝脂肪变性改善优于辛伐他汀组，炎症因子降低（P<0.05）。临床研究中，观察组29例、对照组31例完成试验。观察组治疗后体质量、空腹血糖、甘油三酯、糖化血红蛋白及肝酶水平改善（P<0.05），空腹血糖水平低于对照组（P<0.05），两组总有效率相近（P>0.05）。 结论 降脂祛斑方通过多成分协同作用，可能主要通过调控炎症-代谢网络发挥治疗2型糖尿病合并高脂血症的效果。

关键词: 降脂祛斑方, 2 型糖尿病, 高脂血症, 网络药理学

Abstract:

Objective To explore the therapeutic mechanism of Jiangzhi Quban Recipe (JZQBR) for type 2 diabetes mellitus (T2DM) complicated with hyperlipidemia and validate its clinical efficacy and safety. Methods The active components and disease targets of JZQBR were screened using TCMSP and GeneCards databases, followed by protein-protein interaction analysis and GO and KEGG enrichment analyses. In the animal experiments, ApoE-/- mice were randomized into blank control, model, simvastatin treatment, and low- and high-dose JZQBR groups. In the latter 4 groups, the mice were fed a high-fat diet for 24 weeks with corresponding treatments from Weeks 9 to 24. The changes in body weight, blood glucose, lipids, liver pathology, and inflammatory cytokine expressions of the mice were examined. In the clinical study, 72 T2DM patients with hyperlipidemia were randomized equally into control group for treatment with metformin plus empagliflozin and JZQBR group with additional JZQBR for 12 consecutive weeks. Results Network pharmacology identified 65 potential targets, with quercetin, kaempferol, and luteolin as the core components and IL-6, IL-1β, and TNF‑α as the key targets. The targets were enriched mainly in the pathways involving inflammatory responses and diabetic complications. In the ApoE-/- mouse models, JZQBR treatment dose-dependently improved body weight, blood glucose, and blood lipid profiles, and high-dose JZQBR produced a stronger effect than simvastatin for improving hepatic steatosis and significantly reduced inflammatory cytokine levels. In the clinical trial, 29 patients in JZQBR group and 31 in the control group completed the trial. The patients in JZQBR group showed significant improvements in body weight, FBG, TG, HbA1c, and liver enzymes with significantly lower fasting blood glucose level than the control group. The total effective rates were comparable between the two groups. Conclusion JZQBR improves T2DM complicated with hyperlipidemia possibly by multi-target regulation of the inflammation-metabolism network.

Key words: Jiangzhi Quban recipe, type 2 diabetes mellitus, hyperlipidemia, network pharmacology